glp 1 switzerland GLP-1s: The Swiss Army Knife Tackling More Than Obesity The GLP-1 Access Gap: Mapping

The current therapeutics for managing diabetes and the related kidney disease include sodium glucose cotransporter-2 inhibitors (SGLT2is), blood pressure-lowering agents such as angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), N-acetyl-seryl-lysyl-proline (AcSDKP), non-steroidal mineralocorticoid receptor (MR) antagonists, and glucagon-like peptide-1 (GLP-1) receptor agonists (Srivastava et al., 2020a

Only available for subscriptions

WATCH | Benefits of GLP-1s explored beyond weight loss: Health Canada spokesperson Marie-Pier Burelle said tirzepatide should be injected once a week and used alongside a reduced calorie diet and increased physical activity in adults with obesity, measured by a body mass index (BMI) of 30kg/m2 or higher

difficile may need to be discontinued

STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD